Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Natalizumab 1Interferon beta-1b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Sclerosis, Chronic Progressive × Clear all
NCT03283826 2024-02-23

EMBOLD

Atara Biotherapeutics

Phase 1/2 Terminated
134 enrolled

Autoimmune Diseases, Demyelinating Diseases, Inflammation, Multiple Sclerosis, Epstein-Barr Virus Infections, Multiple Sclerosis, Chronic Progressive

NCT03134573 2019-03-26

PROmyBETAapp

Bayer

Completed
96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

NCT01416181 2017-09-11

ASCEND in SPMS

Biogen

Phase 3 Terminated
889 enrolled 31 charts

Multiple Sclerosis, Neoplasm Metastasis, Multiple Sclerosis, Chronic Progressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡